IMGT Corp Ltd
IMGT Corp Ltd has a negative equity position of KRW -60,189,027,960 and a debt-to-equity ratio of -0.31, indicating a significant reliance on debt financing and a weak capital structure. The company's liquidity is further constrained by a current ratio of 0.18, suggesting limited ability to meet short-term obligations. Despite holding KRW 6,104,918,390 in cash and equivalents, the company's operating cash flow is negative at KRW -4,829,577,710, and its free cash flow is KRW -39,779,571,840, highlighting a severe cash outflow problem. Profitability metrics are deeply negative, with a return on equity of 0.664 and a return on assets of -2.6432. These figures indicate that the company is not generating returns that exceed its cost of capital and is underperforming relative to industry norms. The company's operating income is negative at KRW -5,621,738,510, and its net income is KRW -39,965,654,940, reflecting a substantial loss-making position. The company's revenue is reported as KRW 0, suggesting either a lack of commercialization or a reporting anomaly. There is no disclosed segment or geographic breakdown of revenue, making it difficult to assess the concentration of risk or growth potential in specific markets or product lines. Looking ahead, the company is projected to continue experiencing negative revenue and operating performance, with no clear path to profitability. The absence of revenue and the negative operating cash flow suggest a high risk of insolvency in the near term. The company's capital expenditure of KRW -229,015,900 indicates ongoing investment, but without a corresponding increase in revenue, this spending is not contributing to value creation. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which is a key flag for liquidity concerns. The low dilution risk is attributed to the absence of significant dilution sources in the current financial structure. Recent events and filings do not provide additional insight into the company's operations or strategic direction. The lack of disclosed revenue and the negative financial performance suggest that the company may be in a development or early-stage phase, with limited commercial success to date.
Business. IMGT Corp Ltd is a Korea-based company engaged in the development and sale of drug delivery systems, focusing on ultrasound-guided therapy technologies such as IMGT-LPS, IMGT-EMB, and IMGT-TSD, as well as non-invasive treatment devices like IMGT-FUS.
Classification. IMGT Corp Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Biotechnology & Medical Research industry, with a classification confidence of 0.92.
- IMGT Corp Ltd is operating at a significant loss with a negative net income of KRW -39,965,654,940.
- The company's capital structure is heavily leveraged, with a debt-to-equity ratio of -0.31 and a negative equity position.
- Liquidity is a major concern, as evidenced by a current ratio of 0.18 and negative operating cash flow.
- The company's financial performance is not generating returns that exceed its cost of capital, with a return on equity of 0.664 and a return on assets of -2.6432.
- There is no disclosed revenue, indicating either a lack of commercialization or a reporting issue.
- # RATIONALES
- **margin_outlook_rationale**: The company's margin outlook is negative due to its deep operating and net losses, which indicate a failure to generate sufficient revenue to cover costs.
- **rd_outlook_rationale**: The company's R&D outlook is uncertain, as there is no disclosed investment in R&D or any indication of how R&D spending is contributing to product development or commercialization.
- Net cash is negative after subtracting total debt.